Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer-Reference-Cited by-同舟云学术

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

Published:2012-10-09 Issue:10 Volume:107 Page:1776-1782
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Abkevich V,Timms K M,Hennessy B T,Potter J,Carey M S,Meyer L A,Smith-McCune K,Broaddus R,Lu K H,Chen J,Tran T V,Williams D,Iliev D,Jammulapati S,FitzGerald L M,Krivak T,DeLoia J A,Gutin A,Mills G B,Lanchbury J S

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2012451.pdf

Reference26 articles.

1. Beaudet AL, Tsui LCA (1993) A suggested nomenclature for designating mutations. Hum Mutat 2: 245–248

2. Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, Richardson AL (2012) Telomeric allele imbalance indicated defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2: 366–375

3. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913–917

4. Byler Dann R, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake DD, Lanchbury JS, Krivak TC (2012) BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced epithelial ovarian cancer. Gynecol Oncol 125: 677–682

5. Cerbinskaite A, Mukhopadhyay A, Plummer ER, Curtin NJ, Edmondson RJ (2011) Defective homologous recombination in human cancers. Cancer Treat Rev 38: 89–100

Cited by 611 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genomic Insights Into High-Grade Infarct-Associated Bone Sarcomas;Modern Pathology;2024-10

2. Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma;npj Precision Oncology;2024-09-05

3. Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitors;Journal of the National Cancer Center;2024-09

4. Diagnostics and treatment of BRCA-associated cancers with olaparib — expert position statement;Oncology in Clinical Practice;2024-08-21

5. Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches;Frontiers in Oncology;2024-08-16